Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | SYK | P43405 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.50 |
| ▸ | NMT1 | P30419 | 3/20 | 0.49 |
| ▸ | XBP1 | P17861 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NMT2 | O60551 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | FOS | P01100 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1313596 | 0.89 | SYK (0.79) | MAPTLMNASYKMAPK1HTT | |
| SCHEMBL30879308 | 0.86 | MAPT (0.80) | MAPTLMNASYKMAPK1HTT | |
| SCHEMBL16274792 | 0.83 | ALDH1A1 (0.60) | MAPTLMNASYKMAPK1HTT | |
| SCHEMBL1353552 | 0.82 | SYK (1.00) | MAPTLMNASYKMAPK1HTT | |
| SCHEMBL7797838 | 0.82 | SYK (0.80) | MAPTLMNASYKMAPK1HTT | |
| SCHEMBL6338112 | 0.82 | SYK (0.80) | MAPTLMNASYKMAPK1HTT | |
| SCHEMBL23633154 | 0.82 | MAPT (0.74) | MAPTLMNASYKMAPK1HTT | |
| SCHEMBL445955 | 0.80 | ALDH1A1 (0.65) | MAPTLMNASYKMAPK1HTT | |
| SCHEMBL15584081 | 0.80 | ALDH1A1 (0.63) | MAPTSYKMAPK1HTTALDH1A1 | |
| SCHEMBL2627146 | 0.80 | SYK (0.75) | MAPTLMNASYKMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220098203-A1 | AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | LES LABORATOIRES SERVIER (FR) | 2022-03-31 | — | — | US | disclosed |
| EP-3902804-A1 | AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | Les Laboratoires Servier SAS (FR) | 2021-11-03 | — | — | EP | disclosed |
| CN-113474347-A | AZA heterobicyclic inhibitors of MAT2A and methods for treating cancer | 法国施维雅药厂 | 2021-10-01 | — | — | CN | disclosed |
| WO-2020139992-A1 | AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | AGIOS PHARMACEUTICALS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| WO-2020139992-A1 | AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | AGIOS PHARMACEUTICALS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098203-A1 | AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | MAT2A, MAT2B, MAT1A | MAPT 932/4885LMNA 3133/4885SYK 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.